ProMIS Neurosciences Inc. (PMN) stock
PMNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.13−0.08 (-2.49%)
Close on Nov 18, 2026Market cap $28.07MP/E –Yield –
ProMIS Neurosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ProMIS Neurosciences's operating income for the twelve months ending Jun 30, 2026 was -$43.43M. For fiscal 2025 it was -$40.17M. The highest annual figure on record is -$8.29M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$40.17M | – |
| FY2024 | Dec 31, 2024 | -$16.83M | – |
| FY2023 | Dec 31, 2023 | -$14.26M | – |
| FY2022 | Dec 31, 2022 | -$23.38M | – |
| FY2021 | Dec 31, 2021 | -$8.29M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.64M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.75M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.18M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.46M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.43M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.71M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.87M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.90M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.52M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.05M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.86M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.55M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.07M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.11M | – |
See a number that looks wrong?